相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A survey of 1,475 U.S. adults found that nearly 90% believe it is always best to finish a full course of antibiotics, even when feeling better, reflecting outdated guidance. - About 60% of respondents preferred a longer antibiotic course for pneumonia, despite evidence that shorter courses are equally effective and safer. - A 2023 review of more than 120 randomized controlled trials found short antibiotic courses were as effective as long courses for infections ranging from UTIs to pneumonia. - Researchers urge clinicians and public health campaigns to communicate that shorter courses may reduce side effects and antibiotic resistance, while some conditions like tuberculosis still require longer treatment.
- Researchers at University of Utah Health combined family genetic studies with AI-based molecular biology tools to screen half a million drug candidates, narrowing to six in weeks. - The lead compound, M04, inhibited inflammatory genes and increased expression of genes promoting cartilage cell health in a cell-based osteoarthritis model. - The discovery targets WNK2, a gene linked to hereditary OA, representing a genetically informed approach to treating osteoarthritis at its source rather than managing symptoms. - M04 has not yet been tested in animals or humans; toxicity, side effects, and safety remain unknown, with further development underway through the University of Utah Therapeutics Accelerator Hub.
- The HER Salt Lake Contraceptive Initiative found that when patients receive person-centered counseling and robust access support, failure rates across most birth control methods narrow to approximately 1 pregnancy per 100 participants per year. - The three-year study of over 4,000 participants challenges the long-held assumption that long-acting reversible contraceptives are vastly superior to shorter-term methods like pills or rings. - Researchers emphasize that respecting patient preferences, providing timely access, and removing logistical barriers are critical to improving real-world contraceptive effectiveness. - The findings suggest that patient-centered care can make preferred methods both acceptable and highly effective, reducing the perceived trade-off between liking a method and needing reliable pregnancy prevention.
- Motif Neurotech received FDA approval for the RESONATE early feasibility study to test its XCS System, a wirelessly-powered brain implant for treatment-resistant depression. - The blueberry-sized device delivers electrical stimulation to brain regions without direct brain contact, activated by wearing a baseball hat-like external component. - The trial will evaluate safety and efficacy in patients who have not responded to two or more medications across eight leading medical institutions. - Nearly 3 million Americans live with treatment-resistant depression, representing a significant unmet medical need for this novel brain-computer interface approach.
- A new observational study found that people with diabetes taking GLP-1 drugs had more than twice the risk of developing neovascular age-related macular degeneration compared to those not taking the medications, with risk increasing from 0.1% to 0.2% after one year. - Separate case reports documented nine patients who developed vision-threatening conditions including nonarteritic anterior ischemic optic neuropathy (NAION) after starting GLP-1 medications like semaglutide and tirzepatide. - Researchers emphasize that while the absolute risk remains low, the doubling of risk for advanced AMD is clinically meaningful, particularly for older adults who may already be at elevated baseline risk. - Experts recommend that patients on GLP-1 drugs should promptly report visual symptoms and receive immediate ophthalmologic evaluation, though the findings should not cause alarm or abrupt prescribing changes.
• Preliminary results from the SHIELD-Utah study reveal Novavax's COVID-19 Vaccine (2024-2025 Formula) targeting the JN.1 strain produced fewer and less severe reactogenicity symptoms compared to Pfizer-BioNTech's mRNA vaccine. • Healthcare workers receiving Novavax's protein-based vaccine experienced significantly fewer systemic symptoms (1.7 vs 2.8) and lower rates of Grade 2 or higher symptoms (24.2% vs 43.8%) than Pfizer-BioNTech recipients. • The real-world study demonstrated that Novavax recipients reported less impact on daily activities, with fewer hours of missed work and reduced productivity compared to those who received the Pfizer-BioNTech vaccine.
- The IMPACT trial demonstrates that certolizumab pegol significantly reduces adverse pregnancy outcomes in women with antiphospholipid syndrome, with complication rates dropping from 69-79% to just 20%. - Women treated with certolizumab alongside standard therapy experienced dramatically improved pregnancy duration, averaging 36.5 weeks compared to 24 weeks in their previous pregnancies. - The groundbreaking study reveals that targeting inflammation rather than blood clotting alone may be key to preventing pregnancy complications in APS, with 93% of participants successfully delivering healthy babies.
- Researchers have identified DMT1, an iron transport protein, as crucial for the survival and reproduction of malaria parasites, offering a promising target for new antimalarial drugs. - Blocking DMT1 rapidly kills malaria parasites by impairing multiple aspects of their viability during blood-stage infection, suggesting potential for faster-acting treatments. - The moderate similarity between DMT1 and human iron transporters allows for the possibility of designing parasite-specific inhibitors with minimal impact on human proteins. - Studies showed that when DMT1 activity was reduced, parasite growth slowed, but was restored with extra iron, further confirming DMT1's role in iron transport and parasite survival.
• A clinical trial is underway to compare ketamine and fentanyl for prehospital pain management in trauma patients. • The study seeks to determine if ketamine offers advantages over fentanyl, such as fewer side effects and faster recovery. • Researchers aim to improve analgesia protocols in emergency settings, potentially enhancing patient comfort and outcomes. • Ketamine's potential benefits include a lower risk of respiratory depression and improved blood pressure compared to opioids.
